FI3849976T3 - Gaba a -reseptorin ligandi - Google Patents

Gaba a -reseptorin ligandi Download PDF

Info

Publication number
FI3849976T3
FI3849976T3 FIEP19765747.1T FI19765747T FI3849976T3 FI 3849976 T3 FI3849976 T3 FI 3849976T3 FI 19765747 T FI19765747 T FI 19765747T FI 3849976 T3 FI3849976 T3 FI 3849976T3
Authority
FI
Finland
Prior art keywords
compound
itching
gaba
receptor ligand
skin disease
Prior art date
Application number
FIEP19765747.1T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Janus Larsen
Dipak Amrutkar
Thomas Jacobsen
Tino Dyhring
Karin Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FI3849976T3 publication Critical patent/FI3849976T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP19765747.1T 2018-09-13 2019-09-13 Gaba a -reseptorin ligandi FI3849976T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18194297 2018-09-13
PCT/EP2019/074465 WO2020053377A1 (en) 2018-09-13 2019-09-13 A gabaa receptor ligand

Publications (1)

Publication Number Publication Date
FI3849976T3 true FI3849976T3 (fi) 2023-02-19

Family

ID=63579205

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19765747.1T FI3849976T3 (fi) 2018-09-13 2019-09-13 Gaba a -reseptorin ligandi

Country Status (24)

Country Link
US (1) US11396510B2 (cg-RX-API-DMAC7.html)
EP (1) EP3849976B1 (cg-RX-API-DMAC7.html)
JP (1) JP7353663B2 (cg-RX-API-DMAC7.html)
KR (1) KR102712565B1 (cg-RX-API-DMAC7.html)
CN (1) CN112714765B (cg-RX-API-DMAC7.html)
AU (1) AU2019338236B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004661A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110283A1 (cg-RX-API-DMAC7.html)
DK (1) DK3849976T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190717A1 (cg-RX-API-DMAC7.html)
ES (1) ES2935705T3 (cg-RX-API-DMAC7.html)
FI (1) FI3849976T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230067T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060943T2 (cg-RX-API-DMAC7.html)
IL (1) IL281335B2 (cg-RX-API-DMAC7.html)
LT (1) LT3849976T (cg-RX-API-DMAC7.html)
MX (1) MX2021003010A (cg-RX-API-DMAC7.html)
PH (1) PH12021550299A1 (cg-RX-API-DMAC7.html)
PL (1) PL3849976T3 (cg-RX-API-DMAC7.html)
PT (1) PT3849976T (cg-RX-API-DMAC7.html)
SG (1) SG11202101360VA (cg-RX-API-DMAC7.html)
SI (1) SI3849976T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020053377A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100976B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240197733A1 (en) 2021-04-16 2024-06-20 Saniona A/S A gaba receptor modulator for use in the treatment of pain
EP4777104A1 (en) * 2023-09-15 2026-07-22 Saniona A/S A gaba receptor modulator for treating disorders associated with sleep spindle deficits
EP4777103A1 (en) * 2023-09-15 2026-07-22 Saniona A/S A gaba receptor modulator for use in the treatment of absence seizures
WO2026109691A1 (en) * 2024-11-22 2026-05-28 Saniona A/S A gaba receptor modulator for use in the treatment of tremor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675484B2 (en) 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
GB9702524D0 (en) 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
GB9813576D0 (en) * 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
JP2002535407A (ja) * 1999-01-27 2002-10-22 メルク シャープ エンド ドーム リミテッド Gaba受容体のリガンドとしてのトリアゾロピリダジン誘導体
GB9921150D0 (en) 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
GB0208394D0 (en) * 2002-04-11 2002-05-22 Merck Sharp & Dohme Therapeutic agents
GB0208392D0 (en) * 2002-04-11 2002-05-22 Merck Sharp & Dohme Therapeutic compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
MXPA05010449A (es) 2003-04-03 2006-05-31 Neurosearch As Derivados del bencimidazol y su uso para modular el complejo del receptor de gabaa.
TWI391381B (zh) * 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
TW201029986A (en) 2008-11-14 2010-08-16 Neurosearch As Novel compounds
BR112018015386A2 (pt) 2016-01-27 2019-03-19 Universität Zürich uso de moduladores de receptor gabaa para tratamento de prurido

Also Published As

Publication number Publication date
LT3849976T (lt) 2023-02-10
EP3849976A1 (en) 2021-07-21
PT3849976T (pt) 2023-01-13
US11396510B2 (en) 2022-07-26
HUE060943T2 (hu) 2023-04-28
EA202190717A1 (ru) 2021-09-22
DK3849976T3 (da) 2023-01-23
WO2020053377A1 (en) 2020-03-19
CA3110283A1 (en) 2020-03-19
PL3849976T3 (pl) 2023-02-27
IL281335A (en) 2021-04-29
CN112714765A (zh) 2021-04-27
MX2021003010A (es) 2021-05-27
BR112021004661A2 (pt) 2021-06-01
KR102712565B1 (ko) 2024-10-02
CN112714765B (zh) 2023-06-30
SG11202101360VA (en) 2021-03-30
IL281335B1 (en) 2024-03-01
ZA202100976B (en) 2022-08-31
JP2022500445A (ja) 2022-01-04
US20210332042A1 (en) 2021-10-28
HRP20230067T1 (hr) 2023-03-17
PH12021550299A1 (en) 2021-10-25
ES2935705T3 (es) 2023-03-09
IL281335B2 (en) 2024-07-01
AU2019338236B2 (en) 2025-01-09
SI3849976T1 (sl) 2023-03-31
JP7353663B2 (ja) 2023-10-02
EP3849976B1 (en) 2022-10-26
KR20210061338A (ko) 2021-05-27
AU2019338236A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
HRP20210343T1 (hr) Soli ili ko-kristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
MX2017000612A (es) Inhibidores de tirosina quinasa del bazo (syk).
MX2022006990A (es) Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico.
WO2014151630A3 (en) Compounds and compositions for the treatment of parasitic diseases
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
PH12014500065A1 (en) A new therapeutical composition containing apomorphine as active ingredient
JP2022500445A5 (cg-RX-API-DMAC7.html)
US8318740B2 (en) Compounds for protein kinase inhibition
HRP20230067T1 (hr) Ligand gaba receptora
MX2019012827A (es) Derivados de tetrahidronaftilo urea novedosos.
EA202092361A1 (ru) Конъюгат цитотоксического лекарственного средства и пролекарственная форма указанного конъюгата
EP2796450A4 (en) 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
JP2018145180A5 (cg-RX-API-DMAC7.html)
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
MX2021001563A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
ME02405B (me) Spojevi pirazola као inhibitori sglt1
CA3120726C (en) Rip1 inhibitors
FR3047665B1 (fr) Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
FI4166137T3 (fi) Terapeuttinen aine rasvamaksataudin hoitoon
FI3697795T3 (fi) (R)-9-(2,5-difluorifenetyyli)-4-etyyli-2-metyyli-1-oksa-4,9-diatsaspiro[5.5]undekan-3-onin suoloja
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
AU2017299850A8 (en) Solid forms of TTK inhibitor